This is a specific type of joint inflammation where the lining of the joint gets thickened and filled with special cells. It often affects the hands and feet. It's sometimes called diffuse tenosynovial giant cell tumor.
Every report comes from a Lived member, sent anonymously.
Have you had Synovectomy for Pigmented Villonodular Synovitis?
Pigmented villonodular synovitis (PVNS) is a rare overgrowth of the synovium, the thin lining that cushions and lubricates the inside of a joint. The lining thickens into finger-like and knobby folds and slowly fills the joint, causing swelling, pain, stiffness and loss of movement. The knee is affected in most cases, followed by the hip, ankle and elbow, and it usually involves a single joint. Doctors now call this condition diffuse tenosynovial giant cell tumor (TGCT). The word tumor can be alarming, but PVNS is benign: it is not cancer and very rarely spreads. It is, however, locally aggressive. Left to grow, it can wear away cartilage and bone and lead to arthritis in the joint. A related form, localized TGCT, is a single well-defined lump, often around a finger or wrist tendon, and is usually much easier to treat.
In most cases, the tumor cells carry a rearrangement of genetic material that makes them overproduce a signaling protein called CSF1 (colony-stimulating factor 1). That signal draws in large numbers of immune cells, and these recruited cells make up most of the tumor's bulk. The rusty pigment in the name comes from iron deposits left by small bleeds within the thickened lining. This genetic change arises within the joint tissue itself. Researchers do not know what sets it off, and no habit, injury or diet has been shown to cause PVNS. It most often appears in adults between about 35 and 50, and it is slightly more common in women.
Because PVNS develops slowly and its symptoms resemble more common problems such as a cartilage tear or arthritis, it can take time to diagnose. A clinician will ask about the pattern of swelling and stiffness and examine the joint. MRI (magnetic resonance imaging) is the key test. It shows how far the thickened lining has spread, and the iron deposits give PVNS a distinctive dark appearance on the scan that points strongly toward the diagnosis. X-rays help show whether cartilage and bone have already been damaged. A biopsy, a small tissue sample usually taken with a needle guided by ultrasound or a CT (computed tomography) scan, confirms the diagnosis under the microscope. Because this is a rare disease, assessment at a center with experience in joint tumors is often worthwhile.
Not every case needs immediate treatment. Some people with extensive disease have little pain and stay active, and when symptoms are manageable, regular monitoring with periodic MRI is a reasonable choice. When symptoms interfere with life, surgery to remove as much of the abnormal lining as possible (synovectomy) is the usual first treatment. It can be done through keyhole (arthroscopic) surgery, open surgery or a combination, depending on where the disease extends. The main limitation is that the diffuse form often comes back: roughly 20 to 50 percent of people have a recurrence after surgery, and leaving tissue behind raises that chance. People whose joint is already badly worn, particularly older adults, may do better with a joint replacement. For adults whose tumor cannot be removed without seriously harming the joint, two oral medicines that block the CSF1 signal are approved in the US: pexidartinib (Turalio), taken twice a day, and vimseltinib (Romvimza), taken twice a week. In trials, they shrank tumors in a meaningful share of people and improved pain, stiffness and range of motion compared with a placebo. They control the disease rather than cure it, and they do not reverse joint damage that has already occurred. Pexidartinib can cause serious, sometimes fatal, liver injury, so it requires regular liver blood tests and is available only through a restricted program. Both medicines can harm a developing baby, so pregnancy planning is part of the decision, and vimseltinib also needs liver monitoring. Radiation is now used only rarely, for difficult cases that keep returning, because of its long-term effects on the joint.
PVNS is not life-threatening, but it can be a long-term condition that shapes how you use the affected joint. Many people live with intermittent swelling and stiffness, and some need more than one operation over the years. The main long-term concern is wear on the joint, which can lead to arthritis and eventually joint replacement. After surgery, physical therapy helps restore motion and strength. Follow-up MRI scans are used to watch for regrowth, since recurrence can appear months or years later. For people on medication, follow-up includes regular blood tests and scans, and treatment plans may involve pauses or dose changes. Care is often shared among an orthopedic surgeon, a specialist in joint tumors and, when medication is used, an oncologist, since cancer specialists manage these targeted tumor medicines even though PVNS is not cancer.
Arrange an evaluation if a joint, especially a knee, swells repeatedly or stays swollen and stiff without a clear injury, or if you notice a firm lump near a joint or tendon. Contact your care team if pain, swelling or stiffness returns in a joint that was treated, since this can signal regrowth. If you take pexidartinib, stop it and call your prescriber right away if your skin or the whites of your eyes turn yellow or your urine turns dark, since these can signal liver injury. Report pain under the right ribs, loss of appetite, nausea or unusual tiredness promptly, as these can be earlier signs of the same problem.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Pigmented Villonodular Synovitis is like, what's helped you, or ask the community a question.